Etoricoxib - Tremeau Pharmaceuticals

Drug Profile

Etoricoxib - Tremeau Pharmaceuticals

Alternative Names: TRM-359

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tremeau Pharmaceuticals
  • Class Antirheumatics; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Unspecified

Most Recent Events

  • 29 Nov 2017 Phase-II clinical trials in Undefined indication (In children) in USA (unspecified route) (Tremeau Pharmaceuticals pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top